BC Cancer Agency
CARE + RESEARCH
An agency of the Provincial Health Services Authority

Family Practice Oncology Network

GPO Case Study Day
November 18, 2016
Learning Objectives

Overall: At the conclusion of this case-based CME program, participants will be able to describe and manage key patient care issues related to venous thromboembolism in cancer patients, toxicities of new Checkpoint Inhibition immunotherapies, and breast cancer.

Sessions:

Venous Thromboembolism in Cancer Patients

- Describe and manage key patient care issues related to venous thromboembolism in cancer patients, side-effects of cancer related immunotherapies, and breast cancer
- Identify and address the unique challenges in management of cancer associated thrombosis;
- Recognize patients at high risk of cancer associated thrombosis; and
- Identify and treat cancer patients who require Thromboprophylaxis.

Toxicities in new Checkpoint Inhibition Immunotherapies

- Describe the mechanisms of action of the new immunotherapies, PD-1 inhibition and Immune Checkpoint inhibition;
- Describe the difference between new immune therapies and targeted therapies;
- Identify and effectively carry out surveillance of immune related adverse events with these therapies; and
- Institute appropriate management and treatment for immune related adverse events associated with these therapies.

Breast Cancer: Adjuvant

- Describe the principles involved in designing individualized adjuvant breast cancer therapy, including the role of oncotype DX testing;
- Breast Objecti Discuss the risks and benefits of adjuvant chemotherapy, including the management of side-effects; and
- Review the indications for endocrine treatment in pre and post-menopausal women with breast cancer.

Breast Cancer: Metastatic

- Develop an approach to management of breast cancer patients with metastatic disease, including treatment sequencing and the use of novel agents;
- Discuss an approach to managing the frail elderly population with metastatic breast cancer; and

- Review the role of personalized oncogenomics in treating patients with incurable breast cancer.